Gabapentin
Product Images NDC 64725-0511

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 64725-0511). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (64725 0511)

Label for Gabapentin 100 mg capsules, showing a 100-count bottle. The label indicates the product is Rx only, manufactured by Actavis, and repackaged by TYA Pharmaceuticals, located in Tallahassee, FL. It includes placeholder lot and expiration information and instructs to see the package insert for dosing details.*

FDA Label Image

0e023a94-figure-01 (Gabapentin Capsule 1)

Chemical structure diagram of gabapentin showing its molecular framework with a cyclohexane ring attached to an aminomethyl and acetic acid functional groups.*

FDA Label Image

0e023a94-figure-02 (Gabapentin Capsule 2)

A line graph showing mean pain score over 7 weeks with three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and 4-week fixed dose period. The y-axis shows mean pain score from 0 to 10. Both gabapentin doses show a reduction in pain score compared to placebo throughout the study.*

FDA Label Image

0e023a94-figure-03 (Gabapentin Capsule 3)

A bar chart comparing the percentage of responders at endpoint for placebo (PBO) and Gabapentin (GBP) at different dosages in two studies. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

0e023a94-figure-04 (Gabapentin Capsule 4)

A scatter plot comparing differences (%) against daily doses (mg) of gabapentin in three studies labeled a, b, and c. The x-axis shows daily doses at 600, 900, 1200, and 1800 mg, and the y-axis shows percent differences ranging from 2% to 22%. Data points for each study are marked by different symbols: filled squares for study a, crosshatched squares for study b, and empty squares for study c.*

FDA Label Image

0e023a94-figure-05 (Gabapentin Capsule 5)

A line graph showing mean pain scores over eight weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from Baseline to Week 8, while the y-axis shows mean pain scores ranging from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed-dose period, with Gabapentin showing a consistent decrease in pain scores compared to placebo.*

FDA Label Image

0e023a94-figure-06 (Gabapentin Capsule 6)

FDA Label Image

0e023a94-figure-07 (Gabapentin Capsule 7)

FDA Label Image

0e023a94-figure-08 (Gabapentin Capsule 8)

Gabapentin 25 mg oral capsule bottle label from TYA Pharmaceuticals. The amber bottle is shown with a white and orange label displaying the product name, strength, dosage form (oral capsule), and labeler name. The bottle contains 100 capsules as indicated on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.